

David A. Smelson, Psy.D.

WORK ADDRESS:

University of Massachusetts Medical School
Department of Psychiatry
55 Lake Avenue North
Worcester, MA 01655-0002
Phone: 508-856-3768 Ext 15122
FAX: 508-856-6426
Emails: David.smelson@umassmed.edu

Edith Nourse Rogers Memorial Veterans Hospital
200 Springs Road
Bedford, MA 01730

UNDERGRADUATE EDUCATION:

1986-1988 BPS College for Human Services, New York, New York.

GRADUATE EDUCATION:

1988-1989 MS Upsala College, East Orange, New Jersey
1991-1995 Psy.D. Illinois School of Professional Psychology, Chicago, Illinois.

PREGRADUATE TRAINING:

1993-1994 Externship University of Chicago

POSTGRADUATE TRAINING:

1994-1995 Internship University of Medicine and Dentistry New Jersey Medical School

ACADEMIC APPOINTMENTS:

1995-97 Visiting Faculty Dupont Pharma
1997-98 Clinical Instructor Department of Psychiatry, UMDNJ-New Jersey Medical School
1997-99 Visiting Professor Adelphi University, Derner Graduate School of Psychology
1997-2000 Assistant Professor of Internal Medicine Seton Hall Graduate School, of Medical Education
1998-2003 Assistant Professor, Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School
2000-2003 Assistant Professor, UMDNJ-New Jersey Medical School
2001-02 Visiting Professor, Rutgers University Center for Alcohol Studies
2003-Present Associate Professor, Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School
2005-2007 Associate Professor, Department of Psychosocial Rehabilitation and Behavioral Health Care, UMDNJ-School of Health Related Professions
2008-2009 Professor, Department of Psychosocial Rehabilitation and Behavioral Health Care, UMDNJ-School of Health Related Professions.
2008-Present Professor, Department of Psychiatry, University of Massachusetts Medical School.

CLINICAL /RESEARCH APPOINTMENTS:

- 1995-97 Staff Psychologist, Veterans Administration Hospital, East Orange, New Jersey.
1997 Associate Director of the Day Treatment Center, Veterans Administration Hospital, Lyons, New Jersey.
1997-99 Director of the Day Treatment Center Veterans Administration Hospital, Lyons, New Jersey.
1999-2001 Site Coordinator of the Mental Illness, Research, Education and Clinical Center, Veterans Administration New Jersey Health Care System, Lyons and East Orange Campuses.
2001-2004 Director of Time Limited Case Management Services, Veterans Administration New Jersey Health Care System, Lyons and East Orange Campuses.
2000-2005 Director of Psychosis and Dual Diagnosis Research, Veterans Administration New Jersey Health Care System, Lyons and East Orange Campuses.
2005-2007 Director of Psychosis and Dual Diagnosis Programs and Services, Veterans Administration New Jersey Health Care System, Lyons and East Orange Campuses.
2008-Present Director of Translational Research, Edith Nourse Rogers Memorial Veterans Hospital
2008-Present Director of Dual Dx for VA New England Health Care System (Network 1)
2008-Present Vice Chair of Clinical Research, Department of Psychiatry, University of Massachusetts Medical School.

LICENSURE: New Jersey Board of Psychological Examiners License # 3686, 1998
National Register Health Service Provider #51947, 2007

PROFESSIONAL ORGANIZATIONS:

- 1994-95 Society for Psychotherapy Research
1993-Present American Psychological Association

AWARDS AND HONORS:

- 1995 Ariadne P. Beck Psychotherapy Process Research Award, Illinois School of Professional Psychology, Chicago Illinois.

EDITORIAL BOARDS:

- 2007-09 Journal of Dual Diagnosis

JOURNAL REVIEWER:

- Psychiatric Rehabilitation Skills
Neuropsychopharmacology
Psychology of Addictive Behaviors
Journal of Nervous and Mental Diseases
Addiction
Neuropsychopharmacology
Archives of General Psychiatry
Psychiatry Research
Journal of Dual Diagnosis
Biological Psychiatry
Current Topics in Medicinal Chemistry
The European Journal of Psychiatry
Journal of Clinical Psychiatry
Journal of Clinical Psychopharmacology

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

- 2003 National Institute of Drug Abuse Reviewer for CEBRA Proposals
2004 National Institute of Drug Abuse Reviewer for Special Emphasis Panel
2006 VA Health Care System Psychosocial Rehabilitation and Recovery Panel for Special Purpose Appropriation Funding.
2009 National Institute of Drug Abuse Reviewer Special Emphasis Panel/Scientific Review Group

MAJOR COMMITTEE ASSIGNMENTS:

- 1996-98 Coordinator of Continuing Education for Psychology Service, Veterans Administration Hospital, East Orange, New Jersey.
1996-2008 Coordinator of Research Activities for MH&BS, Veterans Administration New Jersey Health Care System.
1998-2008 Institutional Review Board Human Studies Committee Member Veterans Administration New Jersey Health Care System.
1999-2002 Executive Committee Member State-wide Addiction Consortium. The executive Committee was made up of representatives from the VA New Jersey Health Care System, UMDNJ-Robert Wood Johnson Medical School and The Rutgers University Center for Alcohol Studies, Consortium.
2001-2007 Training Committee for Addiction Psychiatry PGY-V Residency Program, UMDNJ-Robert Wood Johnson Medical School
2002 Recovery Training Committee-Served on the training committee that developed the second EES supported web-based recovery training conference.
2002-2004 Board of Trustees, Veterans Biomedical Research Institute.
2004 Co-Chair VA Dual Diagnosis Task Force-Charged by VA SMI Committee to do a need assessment and make recommendations to for dual diagnosis care.
2005-2006 VA Psychosocial Rehabilitation Training Committee-working with EES to develop a national web-based training program for the VA system
2006-present Member of the VA Mental Health QUERI.
2006-Present Chair, VA Mental Health QUERI Dual Diagnosis Workgroup
2006-Present Co-Chair of VA/DOD Dual Diagnosis Clinical Practice Guidelines
2007-present Member of the VA Substance Abuse Disorders QUERI
2008 Commonwealth of Massachusetts, Department of Mental Health Committee on Inpatient Continuing Care
2008 Commonwealth of Massachusetts, Department of Mental Health Committee on Academic Affiliations
2008-Present Member of the Commonwealth of Massachusetts Substance Abuse and Mental Health Services Policy Academy Team for Returning OIF/OEF veteran and Families
2008 - Present Executive Committee, Center for Mental Health Services Research, UMass Medical School
2009 Edith Nourse Rogers VA Medical Center Research and Development Committee
2009-Present Clinical Research Leadership Committee, UMMS Department of Psychiatry (Chair)

FACULTY ADVISOR OF CANDIDATES FOR POSTGRADUATE DEGREE:

1997 - 1999 Adelphi University: Genata Carol, Ph.D.
2008-Present Hofstra University: Stephanie Rodrigues, Ph.D. Candidate

SPONSORSHIP OF POSTDOCTORAL FELLOWS:

1998-Present VA New Jersey Health Care System Addiction Research Post-Doctorate Fellows

1998-1999: Aron Starosta, Ph.D.
1999 -2000: Craig Davis, Psy.D.
2001-2003: Kathy Castles-Fonseca, Psy.D.
2003-2004: Bradley Sussner, Ph.D.
2005-2006: Silvija Gjonbalaj-Marovic, Ph.D.
2008-2009: Kathryn Bottonari, Ph.D.

FACULTY MENTORING:

2008-Present: Amy Wagholtz, Ph.D.
2008-Present: Jessica-Edwards George, Ph.D.
2008-Present: Marsha Ellison, Ph.D.
2008-Present: Rosalie Torres-Stone, Ph.D.
2008-Present: Barry Feldman, Ph.D.
2008-Present: Tatyana Sheinlukht
2008-Present: Eric Smith, M.D.
2008-Present: Gina Vincent, Ph.D.
2009 Sarah Guzofski, M.D.

TEACHING RESPONSIBILITIES:

UMDNJ-New Jersey Medical School-Newark
1997-1999 Substance Abuse Clerkship for Medical Students, Coordinator
1998-2002 Diagnostic Interviewing for Second Year Medical Students

UMDNJ-Robert Wood Johnson Medical School.

1999-Present Addiction Psychiatry PGY-V Residency Program, Supervisor
1998-Present Third Year Medical Students Psychiatry Clerkship - Addiction Lectures
1998-Present Supervisor for Addiction Psychiatry postdoctoral Training Program
2003-Present Co-Site Director of the Addiction Psychiatry Fellowship-VA Component.

CLINICAL RESPONSIBILITIES:

1995-Present Staff Psychologist. Veterans Administration New Jersey Health Care System.

CURRENT RESEARCH GRANT SUPPORT:**As Principal Investigator:**

Health and Human Services-Center for Substance Abuse Treatment # T116576, Award Amount \$1,968,071. Title: Maintaining Independence and Sobriety through Systems Integration, Outreach and networking: The MISSION Program. PI David Smelson, Co-PI Anna Kline, Co-I Douglas Ziedonis, Bradley Sussner, Miklos Losonczy. October 2004-September 2010

VA HSR&D Merit Review Grant # IIR-020-145, Award Amount \$686,909. Title: A Brief Community Linkage Intervention for Dually Diagnosed individuals. PI David Smelson, Co-I's Miklos Losonczy, Anna Kline, Bradley Sussner, Douglas Ziedonis, Fred Blow. February 2005-October 1, 2009

National Institute for Health Grant # R21 AT001350 Award Amount \$586,063. Title Qigong Therapy for Treating Cocaine Addiction. PI David Smelson, Co-I Kevin Chen, Douglas Ziedonis, Anna Kline. June 2005-May 2010.

National Institute of Health R03 DA020434-01 \$155,500. Cue-elicited Craving and Genetics in Cocaine Dependence. PI David Smelson, CO-I's Paul Manowitz, Jay Tishfield, Anna Kline, Paul Lehrer, Bradley Sussner, Doug Ziedonis. September 2005-September 2009.

VA HSR& RRP 08-253 \$75,000. Title: Addressing Tobacco Through Organizational Change in the Community Based outpatient Clinics. PI David Smelson, CO-I's Tatyana Sheinlukht, David Kalman September, 2009-September, 2010

As Co-Principal Investigator or Co-Investigator:

VA HSR&D Merit Review SDP 07-034 \$897,755. Title: Telephone care coordination for smokers in mental health clinics. PI Scott Sherman, CO-PI David Smelson February 2008-October 1, 2011

Health and Human Services-Center for Mental Health Services, Award SM 58804-01 Amount \$2,168,071. Title: MISSION Direct Vet. PI: Deb Pinals, M.D.; Co-PI: David Smelson; Co-I: Carl Fulwiler, M.D., Ph.D., William Fisher, M.D., Al Grzinskis, J.D. September, 2008- September 2013

National Institute of Drug Abuse \$780,000. Memantine-enhanced buprenorphine treatment for opioid dependent young adults. PI: Gerardo Gonzales, CO-Investigators David Smelson, Carl Fulwiler, Gregg Digirolamo. August, 2009-September, 2012

National Institute of Drug Abuse \$1,10,145. "IHEAL. PI Ed Boyer. Co-I's ,Rosalyn Piccard, David Smelson, Doug Ziedonis

VA HSR&D RRP \$100,000. Title: Supporting Education of OIF/OEF Veterans with Disabilities. PI Marsha Ellison, Co-PI, David Smelson" May, 2009-June, 2010

VA HSR&D Merit Review RRP \$72,444. Title: Creating a VA Tobacco Control Implementation Research Collaborative. PI Scott Sherman, CO-PI David Smelson July, 2009-July 2011

FUNDED RESEARCH COMPLETED:

As Principal Investigator:

Veterans Administration Millennium Funding \$414,000. Transitional Treatment Interventions-Time-limited Case Management. PI David Smelson. CO-PI Miklos Losonczy, Douglas Ziedonis, M.D., M.P.H

Lilly Research Laboratories-Investigator initiated study \$56,250. A study of the efficacy of olanzapine and haloperidol in decreasing cue-elicited craving and relapse in withdrawn cocaine dependent patients. PI David Smelson, Psy.D.

Janssen Research Foundation-Investigator initiated study \$42,500. The efficacy of risperidone in decreasing cue-elicited craving in withdrawn cocaine dependent patients. PI David Smelson, Psy.D.

Janssen Research Foundation-Investigator initiated study \$59,100. The efficacy of risperidone as an anti-cocaine craving agent in withdrawn cocaine dependent patients. PI David Smelson, Psy.D.

Veterans Administration Award Amount \$864,434. Time-Limited Case management for Chemically Addicted Mentally Ill. PI David Smelson. Co-PI Anna Kline, CO-I's Bradley Sussner, Miklos Losonczy, Douglas Ziedonis.

AstraZeneca Investigator initiated study \$70,000. Implement of clinical practice guidelines in schizophrenia and other psychotic disorders. September 2001 to September 2008. PI David Smelson. CO-PI John Williams, Miklos Losonczy

Janssen Research Foundation Investigator initiated study \$70,000. A pilot study to evaluate the implementation phase of clinical practice guidelines in schizophrenia and other psychotic disorders. September 2001 to September 2008. CO-PI John Williams, Miklos Losonczy

Lilly Research Laboratories Investigator initiated study \$70,000. An examination of the implement of clinical practice guidelines for the treatment of schizophrenia and other psychotic disorders. September 2001 to September 2008. PI David Smelson. CO-PI John Williams, Miklos Losonczy

Bristol Meyers Squib-Investigator initiated study \$49,100. The efficacy Abilify as an anti-cocaine craving agent in cocaine dependent Schizophrenics. PI David Smelson, Psy.D. CO-PI Douglas Ziedonis

AstraZeneca Investigator initiated study \$89,500. The efficacy of quetiapine for reducing craving and relapses in individuals with schizophrenia and cocaine dependence. PI David Smelson. CO-PI John Williams, Miklos Losonczy

Health and Human Services-Center for Mental Health Services \$199,836. Title: The MISSION fidelity project. PI David Smelson. Co-PI Anna Kline, CO-I's Bradley Sussner, Douglas Ziedonis, Miklos Losonczy. September 2006-September 2008

As Co-Investigator:

Veterans Administration Cooperative Studies Program. Cooperative Study 451: The clinical and economic impact of olanzapine in schizophrenia. PI Robert Rosenheck, M.D.

Veterans Administration Research Funding \$293,556. The EMPOWER Program. PI Brad Sussner, Co-PI David Smelson, CO-I's Anna Kline, Miklos Losonczy

Veterans Administration Health Services Research Funding \$1,020,075. Improving antipsychotic adherence among patients with schizophrenia. PI Marsha Valenstein, Co-Investigator David Smelson

National Institute of Drug Abuse \$931,274. "Modifying MET for use with ASI data." PI Douglas Ziedonis, Co-investigator David Smelson

SUBMITTED GRANTS IN REVIEW:

Health and Human Services-Center for Substance Abuse Treatment, Award Amount \$1,968,071. Title: Maintaining Independence and Sobriety through Systems Integration, Outreach and networking: The MISSION Massachusetts Program. PI: David Smelson, Psy.D.; Co-PI: Carl Fulwiler, M.D., Ph.D.; Co-I: Sarah Guzofski, M.D., Linda Weinreb, M.D., Ed Boyer, M.D.

VA HSR&D RRP \$100,000. Title: Addressing Tobacco through Organizational Change in Addictions Treatment Programs. PI David Kalman, Ph.D., CO-PI David Smelson, CO-I Scott Sherman

VA HSR&D Merit Review \$ 792,575. Title: *Chronic Illness with Complexity: Illness Perceptions among Veterans*. PI David Smelson, CO-I Usha Sambamoorthi, Ronnie Elwy

VA HSR&D RRP \$100,000. Title: Supporting Education Goals of OIF/OEF Veterans with PTSD: Pilot Process & Outcome. PI Marsha Ellison, Co-PI, David Smelson”

National Institute of Drug Abuse (\$223,570). Behavioral and Neural Response to Cocaine Cue-reactivity. PI David Smelson; CO-PI Gregg DiGirolamo, CO-I's Gerardo Gonzalez, Douglas Ziedonis

National Institute of Drug Abuse \$1,970,000. “Center for Adolescent Medications Development. PI Gerardo Gonzalez, Co-investigator; Sun Kim, Lisa Fortuna, David Smelson

National Institute of Drug Abuse. Award Amount 498,764. Title: Longitudinal Study of Drug Use among Persons with SMI. PI: Bill Fisher: CO-PI's David Smelson, Evelyn Bromett.

PUBLICATIONS:

Refereed Original Articles in Journals

1. Roy, M., **Smelson, D.A.**, & Roy, A. (1996). Abnormal electroretinogram in cocaine dependent patients: Relationship to craving. British Journal of Psychiatry 168, 507-511.
2. Roy, M., **Smelson, D.A.**, & Lindeken, S. (1996). Screening for pathological gambling among inpatient substance abusers. British Journal of Psychiatry 169, 523.
3. **Smelson, D.A.**, Kordon, M., & Rudolph, B. (1997). Evaluating the diagnostic interview: Obstacles and future directions. Journal of Clinical Psychology 53, 497-505.
4. Roy, M., Roy, A., Williams, J., Weinberger, L., & **Smelson, D.A.** (1997). Reduced blue cone electroretinogram in cocaine dependent patients. Archives of General Psychiatry 54, 153-156
5. Roy, M., Roy, A., **Smelson, D.A.**, & Weinberger, L. (1997). Reduced blue cone electroretinogram in cocaine dependent patients: A replication. Biological Psychiatry 42, 631-633.
6. Roy, M., **Smelson, D.A.**, & Roy, A. (1997). Longitudinal study of blue cone retinal function in cocaine dependent patients. Biological Psychiatry 41, 252-253.
7. Roy, A., Roy, M., & **Smelson, D.A.** (1998). Risperidone, ERG and cocaine craving. American Journal of Addictions 7, 90.

8. Desai, P., Roy, M., Roy, A., Brown, S., & **Smelson, D.A.** (1997). Impaired color vision in cocaine patients. Archives of General Psychiatry 54, 696-699
9. **Smelson, D.A.**, Roy, A., & Roy, M. (1997). The electroretinogram and neuropsychological functioning in cocaine addicts. Canadian Journal of Psychiatry 41, 415.
10. **Smelson, D.A.**, Roy, A., & Roy, M. (1997). Risperidone on neuropsychological test performance in cocaine withdrawn patients. Canadian Journal of Psychiatry 42, 431
11. **Smelson, D.A.**, Roy, A., & Roy, M. (1997). Risperidone diminished cue-elicited craving in withdrawn cocaine dependent patients. Canadian Journal of Psychiatry 42, 984.
12. **Smelson, D.A.**, McGee-Caulfield, E., Bergstein, P., & Engelhart, C. (1999). Initial validation of the Voris Cocaine Craving Scale: A preliminary report. Journal of Clinical Psychology 55, 135-139
13. **Smelson, D.A.**, Roy, A., Roy, M., & Santana, S. (1998). Electroretinogram in withdrawn cocaine dependent patients: Relationship to cue-elicited craving. British Journal of Psychiatry 172, 537-539.
14. **Smelson, D.A.**, Roy, A., Santana, S., & Engelhart, C. (1999). Neuropsychological deficits in withdrawn cocaine dependent males. American Journal of Drug and Alcohol Abuse 25, 377-381.
15. Howanitz, E., Pardo, M., **Smelson, D.A.**, Engelhart, C., Eisenstein, N., & Losonczy, M.F. (1999). The efficacy and Safety of clozapine versus chlorpromazine in geriatric schizophrenics. J Clinical Psychiatry 60, 41-44
16. Ziedonis, D., Williams, J., Corrigan, P., & **Smelson, D.A.** (2000). Management of substance abuse in Schizophrenia. Psychiatric Annals 30, 67-75.
17. **Smelson, D.A.**, Roy, M., Roy, A., Harter, J., Engelhart, C., & Ziedonis, D. (2000). Relationship between the electroretinogram blue cone amplitude and cue-eliciting cocaine craving. In Harris editor, College of Problems of Drug Dependence, 1999. National Institute of Drug Abuse Research Monograph. DHHS Washington D.C.; USGPO
18. **Smelson, D.A.**, Roy, M., Roy, A., & Torshikovic, D. (2001). Electroretinogram blue cone amplitude and cue-eliciting cocaine craving: A replication. American Journal of Drug and Alcohol Abuse 27, 391-397.
19. Carol, G., **Smelson, D.A.**, Losonczy, M.F., & Ziedonis, D. (2001). Alcohol & drug abuse: A preliminary investigation of cocaine craving among persons with and without schizophrenics. Psychiatric Services 52, 1029-1031.
20. **Smelson, D.A.**, Davis, C., Di Piano, R., Johnson, V., Losonczy, M.F., & Ziedonis, D. (2001). Executive and motor functioning among cocaine dependent schizophrenics and non-drug abusing schizophrenics. Journal of Nervous and Mental Diseases 190, 200-202.
21. **Smelson, D.A.**, Losonczy, M., Kaune, M., Williams, J., Davis, C., & Ziedonis, D. (2002). Risperidone treatment in withdrawn cocaine-dependent schizophrenics. Schizophrenia Research 53, 160.

22. **Smelson, D.A.**, Losonczy, M., Kaune, M., Williams, J., Davis, C., & Ziedonis, D. (2002). Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry. 2002 Sep;47(7):671-5.
23. **Smelson, D.A.**, Kilker, C., Starosta, A., Losonczy, M., Kind, J., & Williams, J. (2002). An analysis of cue-reactivity among individuals with schizophrenia compared to cocaine addicts without schizophrenia. Psychiatric Services 53, 1612-6.
24. **Smelson, D.A.**, Losonczy, M., Davis, C., Williams, J., Starosta, A., & Ziedonis, D. (2002). The efficacy of risperidone for decreasing craving and relapses in individuals with schizophrenia and cocaine dependence. Canadian Journal of Psychiatry 47, 671-675
25. **Smelson, D.A.**, Davis, C., Eisenstein, N., Engelhart, C., Williams, J., Losonczy, M.F. & Ziedonis, D. (2003). Neuropsychological functioning among individuals with schizophrenia and cocaine dependence. Journal of Substance Abuse Treatment 24, 75-79
26. **Smelson, D.A.**, Ziedonis, D.M., Losonczy, M.F., Williams, J., & Kaune, M. (2003). A double-blind study comparing olanzapine to haloperidol for reducing cue-elicited craving in individuals with schizophrenia and cocaine dependence. Schizophrenia Research 60, 303.
27. Ziedonis, D., Williams, J.M., & **Smelson, D.** (2003). Serious mental illness and tobacco addiction: A model program to address this common but neglected issue. American Journal of the Medical Sciences 326(4):223-30.
28. Rosenheck, R., Perlick, D., Bingham, S., Mares, W., Collins, J., Warren, S., Leslie, D., Allan, E., Cambell, E., Carof, S., Corwin, J., Davis, L., Douyon, R., Dunn, L., Evans, L., Freska, E., Grabowski, J., Graeber, D., Hertz, L., Kwon, K., Lawson, W., Mena, F., Sheikh, J., **Smelson, D.**, & Smith-Gamble, V. (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia; A randomized controlled study. JAMA 290, 2693-2702
29. **Smelson, D. A.**, Ziedonis, D. M., Williams, J., Losonczy, M.F., Williams, J., & Kaune, M. (2004). A double blind placebo-controlled trial of risperidone for decreasing cue-elicited craving J Subst Abuse Treat. Jul;27(1):45-9.
30. **Smelson, D.A.**, Losonczy, M., Castles-Fonseca, K., Stewart, P., Kaune, M., & Ziedonis, D. (2005). Preliminary Outcomes from a booster case management program for individuals with a co-occurring substance abuse and a persistent psychiatric disorder. Journal of Dual Diagnosis. 3(1) :47-59.
31. **Smelson, D.A.**, Williams, J., Ziedonis, D.M., Losonczy, M.F., & Kaune, M. (2006). The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: A preliminary report. Journal of Clinical Psychopharmacology. Feb;26(1):9-12.
32. Ziedonis, D., **Smelson, D.**, Rosenthal, R., Batki, S., Green, A., Henrey, R., Montoya, I., Parks, R., Weiss, R. (2005) Improving the Care of Individuals with Schizophrenia and Substance Abuse Disorders. Journal of Psychiatric Practice, 11(5): 1-25
33. Sussner, B., **Smelson, D.**, Kline, A., Losonczy, M., Ziedonis, D. (2005). The validity and clinical utility of a brief measure of cocaine craving . Drug Alcohol Depend. 83(3) 233-237.

34. **Smelson, D.**, Tunis, SL, Nyhuis, AW., Faries, DF., Kinon, BJ, Ascher-Svanum, H. (2006) Substance Use and Antipsychotic Treatment Discontinuation in a 1-Year Randomized Open Label Antipsychotic Trial for Schizophrenia. Journal of Clinical Psychopharmacology . 26(6). 666-667.
35. **Smelson, D.A.**, Williams, J., Ziedonis, D.M., Losonczy, M.F., & Kaune, M. (2006). The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: A preliminary report. Journal of Clinical Psychopharmacology. Feb;26(1):9-12.
36. **Smelson, D.A.**, Losonczy, M., Ziedonis, D., Castles-Fonseca, K., & Kaune, M. (2007). Six month outcomes from a booster case management program for individuals with a co-occurring substance abuse and a persistent psychiatric disorder. European Journal of Psychiatry 21 (2): 143-152.
37. Salvatore, S., **Smelson, D.**, Kline, A., Sussner, B., Deitz, E., Lee, C. (2007). Does cognition and impulsivity play a role in program violations in a federal prison substance abuse treatment facility; A preliminary report. Journal of Correctional Health Care. 13(4) 252-256.
38. Fortuna, J. & **Smelson, D.A.** (2008). Phenomenology of Drug Craving. Journal of Psychoactive Drugs. J Psychoactive Drugs. 2008 Sep;40(3):255-61.
39. Sussner, B., Kline, A., **Smelson, D.**, Losonczy, M. Salvatore, S. (2008). The role of psychosocial characteristics in irregular discharge from residential services for homeless veterans Psychological Services. Vol 5(4), Nov 2008, 341-350.
40. Banerjea R., Sambamoorthi U., **Smelson D.**, Pogach LM. (2008). Expenditures in Mental Illness and Substance Use among Veteran Clinic Users with Diabetes. Journal of Behavioral Health Services & Research. Jul;35(3):290-303.
41. Banerjea R., Sambamoorthi U., **Smelson D.**, Pogach LM. (2008) Chronic illness with complexities: mental illness and substance use among Veteran clinic users with diabetes. Am J Drug Alcohol Abuse.;33(6):807-21.
42. Callahan, L., Kline, A., **Smelson, D.**, Losonczy, M. (2009). The relationship between era served and Psychosocial needs among homeless veterans with mental health and Substance Abuse Disorders. In Press. Journal of Dual Diagnosis.
43. Marcia Valenstein, MD; Janet Kavanagh, MS; Todd Lee, PhD; Peter Reilly, RPh; Gregory W Dalack, MD; John Grabowski, MD; David Smelson, PsyD; David Ronis, PhD; Dara Ganoczy, MPH; Emily Woltmann, MSW; Tabitha Metreger, MS; Patricia Wolschon, MSW; Agnes Jensen, BS, CPhT ; Barb Poddig, PharmD; Frederic C Blow, PhD (2009). Using a Pharmacy-Based Intervention to Improve Antipsychotic Adherence Among Patients with Serious Mental Illness. Submitted for Publication.
44. Banerjea R., Sambamoorthi U., **Smelson D.**, Pogach LM. (2009) Mental illness and Substance Use Disorders among Women Veterans with Diabetes. Womens Health IssuesNov-Dec;19(6):446-56.
45. Kalman, D., Kim, S., DiGirolamo, G, Smelson, D., Ziedonis, D. (2010) Addressing tobacco use disorder in smokers in early remission from alcohol dependence: the case for integrating smoking cessation services in substance use disorder treatment programs. Feb;30(1):12-24.

Invited Articles in Journals; Chapters; Books; Other Professional Communications:

46. **Smelson, D.A.** (1991). The effects of an undercover operation on high school students. Adolescent Counselor 4, 41-45.
47. **Smelson, D.A.** (1993). Adolescent substance abuse prevention. New Jersey Medicine 90, 845-849.
48. **Smelson, D.A.** (1995). A Pilot Investigation: The Global Impressions of the Diagnostic Interview Scale. Unpublished Doctoral Dissertation, Illinois School of Professional Psychology, Chicago.
49. Ziedonis, D., Williams, J., Steinberg, M., **Smelson, D.**, Sussner, B., Violette, N., Folds, N. (2005) Addressing tobacco dependence among veterans with psychiatric disorders: A neglected epidemic of major clinical and public health concern. Proceedings of a VA Smoking Cessation Conference. pp 141-169
50. **Smelson, D.A.**, Dixon, L., Craig, T., Remolina, S., Batki, S., Niv, N., Owen, R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders CNS Drugs. 2008;22(11):903-16.
51. **Smelson, D.A** Banerjea R., Craig, T., Sherman, S. Smoking among individuals with a mental illness: Prevalence, impact and intervention strategies. Public Health Matters Newsletter. Department of Veterans Affairs. September, 2008. pp 1-4

BOOK CHAPTERS:

52. Ziedonis, D., Steinberg, M. L., **Smelson, D.**, & Wyatt, S. (2003). Co-occurring addictive and psychotic disorders. In A.W. Graham, T.K. Schultz, M.F. Mayo-Smith, R.K. Ries & B.B. Wilford (eds.) Principles of Addiction Medicine, Third Edition. Chevy Chase, MD: American Society of Addiction Medicine pp.1297-1320.
53. Ziedonis, D. M., Steinberg, M. L., D'Avanzo, K. & **Smelson, D.** Schizophrenia and substance abuse. In Kranzler HR and Rounsaville BJ (eds.) Dual diagnosis and treatment: Substance abuse and comorbid medical and psychiatric disorders 2nd Edition. Marcel Deker: New York, N.Y., 387-436, 2004.
54. Ziedonis, D.M., O'Hea, E., Kreji, D., Berman, J., Smelson, D. (2007). Treatment of Co-occurring psychiatric and substance abuse disorders. In Bowden-Jones, O., George, T., (eds.) Drug Dependence. Cambridge University Press.

TREATMENT MANUALS:

55. Smelson, D.A., Kline, A., Hills, S., Ziedonis, D. (2007). The MISSION Treatment Manual. Substance Abuse and Mental Health Service Administration.
56. Smelson, D.A., Kline, A., Hills, S., Mizzeli, A.; Trip, J. (2007). The MISSION Consumer Workbook. Substance Abuse and Mental Health Service Administration.